Ocular Therapeutix
OCUL
68 hedge funds and large institutions have $147M invested in Ocular Therapeutix in 2018 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 7 closing their positions.
264% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $364K
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
5% more capital invested
Capital invested by funds: $140M → $147M (+$7.02M)
5% more funds holding
Funds holding: 65 → 68 (+3)
0.75% more ownership
Funds ownership: 57.79% → 58.55% (+0.75%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.85M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.2M |
| 3 |
JP Morgan Chase
New York
|
+$479K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$434K |
| 5 |
State Street
Boston,
Massachusetts
|
+$406K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$2.47M |
| 2 |
ACM
Atika Capital Management
New York
|
-$1.43M |
| 3 |
DAM
Deltec Asset Management
New York
|
-$366K |
| 4 |
Millennium Management
New York
|
-$276K |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$245K |
OCUL Hedge Fund Activity: Q2 2018 in Review
68 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2018, worth a combined $147M — up 5% from $140M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new OCUL positions and 7 closed out — a net gain of 3 holders — while 27 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $1.85M. The largest seller was SV Health Investors, cutting an estimated $2.47M.
- 68 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2018, up from 65 in Q1 2018.
- Funds reported $147M of Ocular Therapeutix stock for Q2 2018, up 5% quarter-over-quarter.
- 10 funds opened new Ocular Therapeutix positions in Q2 2018 and 7 closed out, a net change of +3 holders.
- The largest Ocular Therapeutix buyer in Q2 2018 was BlackRock, an estimated $1.85M added.
- The largest Ocular Therapeutix seller in Q2 2018 was SV Health Investors, an estimated $2.47M sold.
Based on aggregated 13F filings for Q2 2018.